Pregnancy registry for Stelara or Tremfya exposure
Treatments studied
Part of Bones, joints & muscles, Digestive system, Genetic & congenital, Immune system & allergy, Skin clinical trials.
This study is a pregnancy exposure registry. It collects information to better understand pregnancy outcomes after exposure to Stelara or Tremfya (medicines used for autoimmune diseases).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You (the pregnant person) were exposed to Stelara (ustekinumab) or Tremfya (guselkumab) during pregnancy
- Or you were exposed within 3 months before the first day of your last menstrual period (LMP)
- You can provide the timing of when the exposure happened during pregnancy
- You can confirm which medicine you were exposed to (Stelara or Tremfya)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This registry collects information about pregnancy outcomes in people with multiple sclerosis (MS) who have taken Kesimpta (ofatumumab) during pregnancy or shortly before it. It may help doctors better understand safety and developmental outcomes for babies.
This study measures how much Tremfya (guselkumab) gets into breast milk for women who are already taking it for conditions like psoriasis or arthritis and choose to breastfeed. It helps understand if the drug passes to the baby.
This trial is a registry that collects information from adults with plaque psoriasis or psoriatic arthritis who are starting a new biologic or other systemic treatment. It helps researchers understand how these treatments are used in real life and what outcomes they may have.
This study looks at skin cells at the single-cell level to predict which psoriasis treatments will work best for you. It may help doctors personalize treatment choices for plaque psoriasis.
This Phase 1 study uses a special camera to track how ustekinumab (a common biologic medicine) spreads in inflamed tissue. It aims to help researchers understand where the drug goes in Crohn’s disease and psoriasis, especially when standard treatments haven’t worked.
This study is testing a medicine called guselkumab (Tremfya) for people with psoriasis who are already taking another biologic medicine, ustekinumab, but need to switch. The goal is to see how well guselkumab works in real-world use.
Hear when a new Psoriasis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.